Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

Inclusion Criteria: * Healthy volunteers, any gender * 18 to 45 years of age, * Subjects must provide signed informed consent prior to participation in any study-related procedures * Body Mass Index between 19,5 and 29 kg/m2 * IOP \</= 21 mmHg in both eyes * Have a BCVA (Best corrected visual acuity) of \>/= 0.8 (20/25) (Snellen scale), or \</= 0.1 (LogMar units)in both eyes * Normal Fluorescein Clearance Test in both eyes * Normal funduscopy in both eyes Exclusion Criteria: * Pregnant or breastfeeding females or those with a positive pregnancy test. Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the hole study. * Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplastic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes * Previous chronic processes or with rebound characteristics that could interfere with study according to the investigator's judgment. * Volunteers who have received pharmacological treatment, including medicinal plants, during the four weeks previous to beginning the study. * Having used anti-cholinergics, betablockers and corticoids sporadically in the last 30 days whichever the route of administration, or any med by ocular or nasal administration route. * Case history of hypersensitivity to meds or any other allergic process * Visual alterations: Previous eye surgery, glaucoma, uveitis or ocular surface pathology (dry eye, blepharitis). * Volunteers with visual alteration with more than 3 dioptres in either eye * Use of contact lenses * Volunteer who has participated in a clinical trial during the past four months before study entry. * Blood or derivate transfusion during the six previous months to study entry * Case history of drug or alcohol abuse or dependence. * Positive result in test drug abuse during selection period * Positive serology results to hepatitis B virus (HbsAg), virus C or HIV * Analytic alterations medically relevant, at investigator's judgement.